The uncertainty around the future of Elevidys hasn’t destroyed Roche’s belief in the potential of gene therapies, the Swiss company’s head of pharma has told Fierce Biotech, as the pharma continues to expand its research reach outside of its traditional oncology focus. Roche and its partner Sarepta Therapeutics both paused trials of Elevidys back in April following the death of a 16-year-old …
Read More »Elevidys fallout hasn’t dented Roche’s hopes for gene therapies
